Investor Presentation Full Year 2021
134
Investor presentation Full year 2021
Providing access to affordable care for vulnerable patients in
every country
.
Novo NordiskⓇ
Finding solutions to improve care for vulnerable patients in every country requires a
multi-faceted approach and actions
Partnerships are essential to reach
vulnerable patients
Identifying vulnerable
populations globally
Map vulnerable patient based on:
。 Minority, migrant or displaced
populations
。 Low socioeconomic status or
limited resources
。 Underserved populations
46 new vulnerability assessments have
been conducted, totalling 67 overall,
reaching 82,000 people
Implementation of action plan to be
done within a year of analysis
completion
ONCD
The NCO antip
Affordable human insulin in low- &
middle-income countries
As of 1 August 2020, ceiling price reduced to 3 USD per
human insulin vial in 76 low and middle income countries
Access to Insulin Commitment is a promise of low-cost
human insulin, reaching est. 1.7 million in 2021 and avg.
price of 2.3 USD/vial
Expanding Changing Diabetes® in Children programme
No child should die from type 1 diabetes with the ambition
to reach 100,000 children by 2030
MITE
GENEVE
ICRC
+
iii
In 2021, nearly 32,000 children reached as four countries
were added, totalling 18
DANISH
RED
CROSS
Donations to World
Diabetes Foundation
and Novo Nordisk
Haemophilia
Foundation
Chronic Care in
Humanitarian Crises
Note: Changing Diabetes® in Children is a public-private partnership between the International Society for Pediatric and Adolescent Diabetes, the World Diabetes Foundation, Roche and Novo Nordisk.View entire presentation